ABBV Stock Risk & Deep Value Analysis
AbbVie Inc
Healthcare • Drug Manufacturers - General
DVR Score
out of 10
What You Need to Know About ABBV Stock
We analyzed AbbVie Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ABBV through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
How Risky Is ABBV Stock?
Overall Risk
Moderate
Financial Risk
Low
Market Risk
Low
Competitive Risk
High
Execution Risk
Medium
Regulatory Risk
High
What Are the Red Flags for ABBV?
- ⚠
Greater-than-expected erosion from Humira biosimilar competition (ongoing)
- ⚠
Pipeline failures or significant delays in key clinical trials
- ⚠
Negative regulatory decisions or unexpected hurdles for new drug approvals
- ⚠
Increased pricing pressure from governments or payers on existing or new drugs
Unlock ABBV Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does AbbVie Inc (ABBV) Do?
Market Cap
$403.83B
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
55,000
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Visit AbbVie Inc WebsiteIs ABBV Stock Undervalued?
Unlock the full AI analysis for ABBV
Get the complete DVR score, risk analysis, and more
Is ABBV Financially Healthy?
P/E Ratio
171.80
Does ABBV Have a Competitive Moat?
Sign in to unlockMoat Rating
🏰 Wide
Moat Trend
Stable
Moat Sources
4 Identified
AbbVie's wide moat is primarily driven by its extensive and continuously replenished portfolio of patented blockbuster drugs, particularly in immunology and oncology. High R&D investment and regulatory hurdles protect these assets, creating significant switching costs for patients and providers. While patent expirations (like Humira's) present challenges, the company's robust pipeline and strategic M&A consistently introduce new proprietary assets to maintain its competitive edge over a 20+ year horizon.
Moat Erosion Risks
- •Major pipeline failures leading to a lack of new blockbuster drugs to offset patent expiries
- •Aggressive and successful biosimilar launches globally, particularly for key products post-Humira
- •Significant government intervention on drug pricing or accelerated generic approvals
ABBV Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive ABBV Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (Estimated late April 2026)
- •Updates on regulatory filings for new indications for Skyrizi and Rinvoq (e.g., ulcerative colitis, Crohn's disease expansion)
- •Presentation of Phase 3 data for select early-stage pipeline assets (e.g., oncology, neuroscience)
Medium-Term (6-18 months)
- •Launch of new product indications in key international markets (2026-2027)
- •Mid-stage clinical trial readouts for innovative therapies (e.g., ADCs in oncology, next-gen immunology assets)
- •Potential strategic partnerships or bolt-on acquisitions to bolster pipeline
Long-Term (18+ months)
- •Sustained growth of non-Humira immunology portfolio (Skyrizi, Rinvoq) replacing Humira revenue
- •Successful commercialization of promising neuroscience (e.g., Alzheimer's, Parkinson's) and oncology assets entering late-stage development
- •Diversification into new therapeutic areas through R&D and M&A
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for ABBV?
- ✓
Acceleration in revenue growth for Skyrizi and Rinvoq surpassing analyst expectations
- ✓
Positive clinical trial readouts for late-stage pipeline assets, particularly in neuroscience or next-gen oncology
- ✓
Consistent dividend increases and prudent capital allocation decisions
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ABBV (AbbVie Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
